Acer Therapeutics Inc. is a pharmaceutical company dedicated to acquiring, developing, and commercializing therapies for rare and life-threatening diseases with significant unmet medical needs. Their pipeline comprises four clinical-stage candidates targeting various conditions, including COVID-19, vascular Ehlers-Danlos syndrome (vEDS), urea cycle disorders (UCDs), Maple Syrup Urine Disease (MSUD), and induced Vasomotor Symptoms (iVMS). These candidates offer a de-risked profile with favorable safety profiles, clinical proof-of-concept data, mechanistic differentiation, and accelerated paths for development through FDA-established programs and procedures.